Stockscreener 앱 받기
5.74
7.29%
0.39
시간 외 거래:
5.72
-0.02
-0.35%
Atossa Therapeutics Inc 주식(ATOS)의 최신 뉴스
Atossa Therapeutics advances endoxifen as new option for DMD management - Traders Union
Atossa Therapeutics (ATOS) price target decreased by 31.37% to 44.62 - MSN
ATOS Ownership | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics, Inc. advances Z-endoxifen pipeline with key U.S. FDA designations into 2026 - Traders Union
Atossa Therapeutics: A 2026 Regulatory Milestone in Sight - AD HOC NEWS
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics Seeks Shareholder Approval for Further Stock Consolidation - AD HOC NEWS
Atossa (NASDAQ: ATOS) CEO Steven Quay granted 65,000 RSUs after reverse split - Stock Titan
Atossa Therapeutics announces issuance of U.S. patent - MSN
Atossa Therapeutics (ATOS) CFO receives 63,000 RSUs over 3 years - Stock Titan
[ARS] ATOSSA THERAPEUTICS, INC. SEC Filing - Stock Titan
[DEF 14A] ATOSSA THERAPEUTICS, INC. Definitive Proxy Statement - Stock Titan
NCCN event spotlights Atossa Therapeutics, Inc. breast cancer innovation - Traders Union
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Entry Recap: Is Atossa Therapeutics Inc a speculative investment2026 Review & Consistent Profit Focused Trading Strategies - baoquankhu1.vn
Risk Off: Is Atossa Therapeutics Inc stock heavily shorted2026 Market WrapUp & Accurate Entry/Exit Alerts - baoquankhu1.vn
ATOS Price Today: Atossa Therapeutics, Inc. Stock Price, Quote & Chart - MEXC
H.C. Wainwright raises Atossa Genetics price target to $25 from $7 - Investing.com
ATOS Receives Significant Price Target Increase from HC Wainwrig - GuruFocus
Atossa Therapeutics (ATOS) Sees Increased Price Target Following Stock Split - GuruFocus
Aug Weekly: Is Atossa Therapeutics Incs growth already priced in2026 Decliners & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Atossa Therapeutics Reports 2025 Financial Results and Advances (Z)-Endoxifen in Rare Diseases and Oncology - Minichart
Atossa Therapeutics (ATOS) Reports Wider-Than-Expected Loss - GuruFocus
Atossa Therapeutics 2025 Annual Report: (Z)-Endoxifen Clinical Development, Intellectual Property, and Regulatory Strategy - Minichart
Atossa Genetics Investors to Decide on Key Corporate Proposals - AD HOC NEWS
ATOS Advances in Drug Development with Strategic Focus - GuruFocus
Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update - Fidelity
ATOSSA THERAPEUTICS INC reports Q4 and full year 2025 results and unveils corporate update - Traders Union
Atossa Therapeutics 2025 10-K: $0.0M Revenue; Net loss $34.8M - TradingView
Atossa Therapeutics (NASDAQ: ATOS) boosts cash options but warns on going concern - Stock Titan
Atossa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
R&D spending jumps as Atossa (NASDAQ: ATOS) advances (Z)-endoxifen programs - Stock Titan
Atossa Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Atossa Therapeutics (NASDAQ: ATOS) asks shareholders to OK 2:1–20:1 reverse split - Stock Titan
Atossa Therapeutics Inc expected to post a loss of $1.14 a shareEarnings Preview - TradingView
Atossa Therapeutics Appoints Two New Medical Directors in Breast Oncology and Rare Diseases - Contract Pharma
The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology - The Globe and Mail
Atossa Therapeutics Strengthens Clinical Leadership Team with th - GuruFocus
Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives - PR Newswire
Atossa hires 2 veteran doctors to steer breast cancer and rare disease trials - Stock Titan
Should I set a stop loss on Atossa Therapeutics Inc2026 Decliners & Growth Focused Stock Pick Reports - baoquankhu1.vn
Atossa Therapeutics announces launch of early-stage DMD program for rare disease awareness - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - Sahm
Atossa presents preclinical data on endoxifen for muscular dystrophy - Investing.com South Africa
Atossa presents preclinical data on endoxifen for muscular dystrophy By Investing.com - Investing.com Australia
Atossa Therapeutics, Inc. Presents Clinical Trial Update On Z-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference - marketscreener.com
Atossa Therapeutics shares clinical trial update for Z-endoxifen at MDA conference - Traders Union
Atossa Therapeutics Presents Clinical Trial Update Highlighting - GuruFocus
Big Money Moves: Is Atossa Therapeutics Inc a potential multi bagger2026 Price Swings & AI Forecasted Entry/Exit Points - baoquankhu1.vn
Muscle biomarker improvement reported in dystrophic mice, Atossa Therapeutics asserts - Traders Union
2.69%
0.25%
자본화:
|
볼륨(24시간):